Literature DB >> 21160581

Could helical tomotherapy do whole brain radiotherapy and radiosurgery?

Youlia M Kirova1, Cyrus Chargari, Sofia Zefkili, François Campana.   

Abstract

Whole brain radiotherapy (WBRT) remains the standard management of breast cancer patients with brain metastases, allowing for symptomatic improvement and good local control in most patients. However, its results remain suboptimal in terms of both efficacy and toxicity. In highly selected breast cancer patients, stereotaxic radiotherapy demonstrates a very good local control with a low toxicity. With the purpose of improving the efficacy/toxicity ratio, we report the association of integrated boost with WBRT in a breast cancer patient with brain metastases. Two and a half years after completion of helical tomotherapy (HT), the patient experienced clinical and radiological complete remission of her brain disease. No delayed toxicity occurred and the patient kept her hair without need of radiosurgical procedure. The HT provided a high dosimetric homogeneity, delivering integrated radiation boosts, and avoiding critical structures involved in long-term neurological toxicity. Further assessment is required and recruitment of breast cancer patients into clinical trials is encouraged.

Entities:  

Keywords:  Brain metastases; Breast cancer; Radiotherapy; Tomotherapy

Year:  2010        PMID: 21160581      PMCID: PMC2999317          DOI: 10.4329/wjr.v2.i4.148

Source DB:  PubMed          Journal:  World J Radiol        ISSN: 1949-8470


  9 in total

1.  Tomotherapy planning of small brain tumours.

Authors:  Slav Yartsev; Tomas Kron; Luca Cozzi; Antonella Fogliata; Glenn Bauman
Journal:  Radiother Oncol       Date:  2005-01       Impact factor: 6.280

2.  Improve the management of patients with skull bone metastases by means of helical tomotherapy.

Authors:  C Chargari; Y M Kirova; S Zefkili; F Campana
Journal:  Support Care Cancer       Date:  2009-03-17       Impact factor: 3.603

3.  Simultaneous infield boost with helical tomotherapy for patients with 1 to 3 brain metastases.

Authors:  Glenn Bauman; Slav Yartsev; Barb Fisher; Tomas Kron; Normand Laperriere; Mostafa Heydarian; Jake VanDyk
Journal:  Am J Clin Oncol       Date:  2007-02       Impact factor: 2.339

4.  Progressive inflammatory breast cancer in patient receiving chemotherapy: the importance of radiotherapy as a part of locoregional treatment.

Authors:  Cyrus Chargari; Youlia M Kirova; Paul Cottu; Rémy J Salmon; Alain Fourquet
Journal:  Radiother Oncol       Date:  2008-09-02       Impact factor: 6.280

Review 5.  Radiotherapeutic management of brain metastases: a systematic review and meta-analysis.

Authors:  May N Tsao; Nancy S Lloyd; Rebecca K S Wong; Eileen Rakovitch; Edward Chow; Normand Laperriere
Journal:  Cancer Treat Rev       Date:  2005-06       Impact factor: 12.111

Review 6.  Breast cancer metastasis to the central nervous system.

Authors:  Robert J Weil; Diane C Palmieri; Julie L Bronder; Andreas M Stark; Patricia S Steeg
Journal:  Am J Pathol       Date:  2005-10       Impact factor: 4.307

7.  Solitary plasmocytoma: improvement in critical organs sparing by means of helical tomotherapy.

Authors:  Cyrus Chargari; Youlia M Kirova; Sofia Zefkili; Lucas Caussa; Malika Amessis; Rémi Dendale; François Campana; Alain Fourquet
Journal:  Eur J Haematol       Date:  2009-03-05       Impact factor: 2.997

8.  Preliminary experience of helical tomotherapy for locally advanced pancreatic cancer.

Authors:  Cyrus Chargari; Francois Campana; Philippe Beuzeboc; Sofia Zefkili; Youlia M Kirova
Journal:  World J Gastroenterol       Date:  2009-09-21       Impact factor: 5.742

9.  Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients.

Authors:  Cyrus Chargari; Youlia M Kirova; Véronique Diéras; Pablo Castro Pena; Pablo Castro Pena; Francois Campana; Paul H Cottu; JeanYves Pierga; Alain Fourquet
Journal:  J Neurooncol       Date:  2009-01-25       Impact factor: 4.130

  9 in total
  2 in total

1.  Further developments for improving response and tolerance to irradiation for advanced renal cancer: concurrent (mTOR) inhibitor RAD001 and helical tomotherapy.

Authors:  Youlia M Kirova; Vincent Servois; Cyrus Chargari; Malika Amessis; Marc Zerbib; Philippe Beuzeboc
Journal:  Invest New Drugs       Date:  2010-12-14       Impact factor: 3.850

2.  Treatment of single or multiple brain metastases by hypofractionated stereotactic radiotherapy using helical tomotherapy.

Authors:  Aiko Nagai; Yuta Shibamoto; Masanori Yoshida; Koichi Wakamatsu; Yuzo Kikuchi
Journal:  Int J Mol Sci       Date:  2014-04-22       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.